Hostname: page-component-848d4c4894-8kt4b Total loading time: 0 Render date: 2024-07-06T10:00:08.076Z Has data issue: false hasContentIssue false
  • English
  • Français

Monoterapia de modafinilo en la depresión

Published online by Cambridge University Press:  12 May 2020

K. R. Kaufman ,
M. A. Menza  and
A. Fitzsimmons
K. R. Kaufman
Affiliation:
Departamento de Psiquiatría, Facultad de Medicina UMDNJ-Robert Wood Johnson, 125 Paterson Street, Suite #2200, NJ 08901, EE.UU Departamento de Neurología, Facultad de Medicina UMDNJ-Robert Wood Johnson, 125 Paterson Street, Suite #2200, NJ 08901, EE.UU
M. A. Menza
Affiliation:
Departamento de Psiquiatría, Facultad de Medicina UMDNJ-Robert Wood Johnson, 125 Paterson Street, Suite #2200, NJ 08901, EE.UU Departamento de Neurología, Facultad de Medicina UMDNJ-Robert Wood Johnson, 125 Paterson Street, Suite #2200, NJ 08901, EE.UU
A. Fitzsimmons
Affiliation:
Departamento de Psiquiatría, Facultad de Medicina UMDNJ-Robert Wood Johnson, 125 Paterson Street, Suite #2200, NJ 08901, EE.UU
Get access

Extract

Los trastornos afectivos refractarios requieren a menudo una polifarmacia rational: antidepresivos de más de una clase, antidepresivos con anticonvulsives y antidepresivos con aumento (litio, tiroides y psicoestimulantes). Mientras que los psicoestimulantes (metilfenidato, dextroanfetamina y pemolina de magnesio) se utilizan por lo general en pacientes comprometidos médicamente [8], para la depresión refractaria [2, 11] o para los trastornos por déficit de atención [5], estos agentes se deberían considerar para el tratamiento en monoterapia de la depresión cuando un paciente no ha tenido éxito en los ensayos terapéuticos antidepresivos, tiene efectos secundarios inaceptables ante los antidepresivos habituales, incluso con respuestas positivas, o no está dispuesto a recibir modalidades de tratamiento diferentes por temor a los efectos adversos potenciales.

Keywords

modafinilodepresióntratamientomonoterapiapsicoestimulantesantidepresivos
Type
Informe Clínico
Information
European Psychiatry (Ed. Española) , Volume 9 , Issue 7 , October 2002 , pp. 464 - 466
Copyright
Copyright © European Psychiatric Association 2002

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

KaufmanKR, MenzaMA, FitzsimmonsA. Monoterapia de modafinilo en la depresión. Eur Psychiatry2002; 17: 167–169.

References

Bibliografía

Engber, TM, Koury, EJ, Denniss, SA, Miller, MS, Contreras, PC, Bhat, RV. Differential patterns of regional c-fos induction in the rat brain by amphetamine and the novel wakefulnesspromoting agent Modafinil. Neurosci Lett 1998;241(2-3): 95-8.CrossRefGoogle ScholarPubMed
Feighner, JP, Herbstein, J, Damlouji, N. Combined MAOI,TCA and direct stimulant therapy of treatmentresistant depression. J Clin Psychiatry 1985;46(6): 206–9.Google Scholar
Ferraro, L, Antonelli, T, Tanganelli, S, O'Connor, WT, Perez de la Mora, M, Mendez-Franco, J, Rambert, FA, Fuxe, KK. The vigilance promotin drug modafinil increases extracellular glutamate levels in the medial preoptic area and the posterior hypothalamus of the conscious rat: prevention by local GABAA receptor blockade. Neuropsychopharmacology 1999;29(4): 346–56.CrossRefGoogle Scholar
Gold, LH, Balster, RL. Evaluation of the cocaine-like dicriminative stimulus effects and reinforcing effects of modafinil. Psychopharmacology (Berlin) 1996; 126:286–92.CrossRefGoogle ScholarPubMed
Jacobvitz, D. Treatment of attentional and hyperactivityproblems in children with sympathomimetic drugs: A comprehensive review. J Am Acad Child Adolesc Psychiatry 1990;29:677–88.CrossRefGoogle ScholarPubMed
Jasinski, DR. An evaluation of the abuse potential of modafinil usin methylphenidate as a reference. J Psychopharmacol 2000;14(1):53–60.Google Scholar
Lin, JS, Hou, Y, Jouvet, M. Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proc Natl Acad Sci. USA 1996;93:14128–33.CrossRefGoogle ScholarPubMed
Masand, PS, Tesar, GE. Use of stimulants in the medically ill. Psychiatr Clin North Am 1996;19(3):515–47.CrossRefGoogle ScholarPubMed
Menza, MA, Kaufman, KR, Castellanos, AM. Modafinilaugmentation of antidepressant treatment in depression. J Clin Psychiatry 2000;61(5):378–81.CrossRefGoogle ScholarPubMed
Robertson, P, DeCory, HH, Madan, A, Parkinson, A. In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil. Drug Metab Dispos 2000;28(6):664–71.Google ScholarPubMed
Stoll, AL, Pillay, SS, Diamond, L, Workum, SB, Cole, JO. Methylphenidate augmentation of serotonin selective reuptake inhibitors: a case series. J Clin Psychiatry 1996;57(2):72–6.Google ScholarPubMed
Wong, YN, Simcoe, D, Hartman, LN, Laughton, WB, King, SP, McCormick, GC, Grebow, PE. A doubleblind, placebocontrolled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers. J Clin Pharmacology 1999; 39(1):30 40.CrossRefGoogle Scholar